Mink Therapeutics
some reasons for limited success of act for solid tumors | Mink Therapeutics
Company
Deck Type
Sector
Industry
Deck date
November 2022
Slide
76 of 92
Related slides by other companies
Enochian Biosciences
Results
August 2023
platform could be applicable to multiple difficult to treat solid tumors | Enochian Biosciences
Recursion Pharmaceuticals
Investor Day
January 2023
for the treatment of solid tumors with mutant cancers | Recursion Pharmaceuticals
AstraZeneca
Investor Event
September 2024
multiple reasons for confidence in success | AstraZeneca
Hyperfine
Investor Presentation
November 2023
solid foundation for long term success user centric ecosystem scalable and low cost | Hyperfine
Other recent decks by Mink Therapeutics
See all presentations (2 decks)
IPO
October 2021
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights